![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, October 09, 2021 9:24:50 AM
After the U.S. Food and Drug Administration (FDA) ordered to hold the clinical-stage biotechnology company’s AlloCAR T clinical trials. Notably, the company develops allogeneic CAR T (AlloCAR T) therapies for cancer.
The U.S. regulator’s decision followed a report of a chromosomal abnormality in ALLO-501A CAR T cells in a patient, who was treated in the ALPHA2 study. The abnormality was detected in a bone marrow biopsy that was undertaken to assess pancytopenia (low blood counts). Notably, an investigation is in progress to detect further implications, if any.
Following discussions with the FDA, the company is likely to provide additional updates. Markedly, the end of Phase 1 materials, which were submitted in anticipation of an ALLO-501A pivotal Phase 2 trial, is under the FDA’s review.
Balanced chromosomal abnormalities can be due to insertions or deletions of genes. This could be a misfire that is known to occur more often with CRSPR process. The anemia may be an autoimmune reaction triggered by the anomaly. ARCUS may be a safer play when it comes to these types of risks.
Recent DTIL News
- Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit • Business Wire • 07/08/2024 11:01:00 AM
- Precision BioSciences Announces its Addition to the Russell Microcap® Index • Business Wire • 07/01/2024 11:01:00 AM
- Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025 • Business Wire • 06/27/2024 11:01:00 AM
- Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness • Business Wire • 06/20/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 09:13:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 09:13:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 09:12:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/10/2024 07:15:20 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/10/2024 07:12:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 12:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:37:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:37:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:37:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:37:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:36:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:36:14 PM
- Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress • Business Wire • 06/05/2024 11:01:00 AM
- Precision BioSciences to Participate in Upcoming June Investor Conferences • Business Wire • 05/30/2024 11:00:00 AM
- Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/17/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 11:15:36 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 11:15:12 AM
- Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update • Business Wire • 05/13/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 12:26:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 12:26:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 12:25:38 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM